Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 28, 2023, titled "Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg".
Press Release Jun 28 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Palbociclib Tablets in various dosages. Palbociclib is indicated for treating a specific type of breast cancer and will be produced at the company's facility in Ahmedabad. The press release highlights that the product had significant annual sales in the United States, indicating its market potential.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 19 2023
- Press Release Jun 13 2023
- Press Release Jun 10 2023
- Press Release Jun 09 2023
- Press Release Jun 08 2023
Later from Zydus Lifesciences
- Press Release Jul 03 2023
- Press Release Jul 04 2023
- Press Release Jul 07 2023
- Press Release Jul 27 2023
- Press Release Aug 03 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences